Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4860 Target Snapshot

Apoptosis regulator Bcl-2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
4,043Compounds
390Assays
5Approved Drugs
7,530.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Apoptosis regulator Bcl-2 shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P10415. Start with chronic lymphocytic leukemia, then reuse UniProt P10415 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with chronic lymphocytic leukemia, then reuse UniProt P10415 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
chronic lymphocytic leukemia

Apoptosis regulator Bcl-2 shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with chronic lymphocytic leukemia because it currently carries approved-linked support. Linked drugs include APG-2575, NAVITOCLAX, OBATOCLAX MESYLATE, VENETOCLAX. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Apoptosis regulator Bcl-2 as ChEMBL target CHEMBL4860, mapped to UniProt P10415. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Apoptosis regulator Bcl-2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4860
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P10415
Apoptosis regulator Bcl-2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Apoptosis regulator Bcl-2 is the right protein anchor across sources, using UniProt P10415 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chronic lymphocytic leukemia is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameApoptosis regulator Bcl-2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP10415
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelApoptosis regulator Bcl-2
UniProt AccessionP10415
Component TypeProtein
Sequence Length239 aa

Apoptosis regulator Bcl-2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Apoptosis regulator Bcl-2, mapped to UniProt P10415. Sequence length is 239 aa.

Mapped IDP10415
Review nameApoptosis regulator Bcl-2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Apoptosis regulator Bcl-2 shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
chronic lymphocytic leukemia
4 linked drugs · 4 direct · 4 efficacy
Linked drugAPG-2575
Linked drugNAVITOCLAX
Linked drugOBATOCLAX MESYLATE
Linked drugVENETOCLAX
Approved-linked Approved
cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugAPG-2575
Linked drugNAVITOCLAX
Linked drugVENETOCLAX
Approved-linked Approved
neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugNAVITOCLAX
Linked drugVENETOCLAX
Late clinical Phase III
acute myeloid leukemia
3 linked drugs · 3 direct · 3 efficacy
Linked drugAPG-2575
Linked drugNAVITOCLAX
Linked drugVENETOCLAX
Late clinical Phase III
Mantle cell lymphoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugNAVITOCLAX
Linked drugOBATOCLAX MESYLATE
Linked drugVENETOCLAX
Late clinical Phase III
multiple myeloma
3 linked drugs · 3 direct · 3 efficacy
Linked drugAPG-2575
Linked drugOBATOCLAX MESYLATE
Linked drugVENETOCLAX
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with chronic lymphocytic leukemia because it currently carries approved-linked support. Linked drugs include APG-2575, NAVITOCLAX, OBATOCLAX MESYLATE, VENETOCLAX. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasechronic lymphocytic leukemia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
12
Phase III
3
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC503,088.0
KI4,198.0
EC5099.0
KD145.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3653966 11.0 Ki 0.01 Preclinical
CHEMBL3952489 11.0 Ki 0.01 Preclinical
CHEMBL3961644 11.0 Ki 0.01 Preclinical
CHEMBL3985475 11.0 Ki 0.01 Preclinical
CHEMBL4228713 11.0 Ki 0.01 Preclinical
CHEMBL5955498 11.0 Ki 0.01 Preclinical
CHEMBL3891622 10.96 Ki 0.011 Preclinical
CHEMBL3900365 10.96 Ki 0.011 Preclinical
CHEMBL5911102 10.96 Ki 0.011 Preclinical
CHEMBL3650632 10.92 Ki 0.012 Preclinical
Distribution

pChEMBL Value Distribution

208
5.0
293
5.5
515
6.0
379
6.5
432
7.0
689
7.5
850
8.0
483
8.5
398
9.0
532
9.5
pChEMBL
Approved Drugs

Approved Drugs

VENETOCLAX
CHEMBL3137309
Approved 2016
Properties Compare Identifier
IXABEPILONE
CHEMBL1201752
Approved 2007
Properties Compare Identifier
Assay Landscape

Assay Landscape

390
Total Assays
3,190
Tested Compounds
4
Assay Types
Binding — 362 assays, 3,190 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 242 2,889 8.3
cell-based format 79 116 7.7
assay format 41 185 6.3
Functional — 23 assays, 55 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 14 6 6.2
assay format 7 49 6.5
organism-based format 2 0 —
Toxicity — 3 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 7 5.8
ADME — 2 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 2 11 6.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine